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HLA = human leukocyte antigen; IL = interleukin; LTR = long terminal repeat; MHC = major histocompatibility complex; NOD = nonobese diabetic;
SSA= Sjögren syndrome antigen A; SSB = Sjögren syndrome antigen B.
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Introduction
Sjögren’s syndrome is an autoimmune exocrinopathy of
unknown aetiology. It is a member of the group of inflam-
matory rheumatic disorders classified as connective tissue
diseases. Clinical experience indicates not only an overlap
among these disorders but also a close relationship of, for
example, autoantibody profiles [1]. The genetic implica-
tions of this overlap has not been extensively explored, and
the genetics behind Sjögren’s syndrome per se are not
well characterized.
There is no single disease-specific diagnostic criterion for
Sjögren’s syndrome. For diagnosis, the most functional
criteria are the recently modified European classification
criteria, which include a list of exclusions [2]. In addition to
the subjective symptoms of dry eyes and dry mouth, the
following objective signs should be present: ocular signs
by Schirmer’s I test and/or Rose Bengal score; focal
sialadenitis by histopathology; salivary gland involvement
by either salivary scintigraphy, parotid sialography or
unstimulated salivary flow; and autoantibodies of Ro/
Sjögren syndrome antigen A (SSA) and/or La/Sjögren
syndrome antigen B (SSB) specificity.
Sjögren’s syndrome occurs worldwide and in all ages.
However, the peak incidence is in the fourth and fifth
decades of life, with a female:male ratio of 9:1. A number of
studies have shown great variation in the frequency of Sjö-
gren’s syndrome (for review [3]). Prevalence studies have
demonstrated that sicca symptoms and primary Sjögren’s
syndrome affects a considerable percentage of the popula-
tion, with precise numbers dependent on the age group
studied and on the criteria used [4]. A cautious but realistic
estimate from the studies presented thus far is that primary
Sjögren’s syndrome is a disease with a prevalence not
exceeding 0.6% of the general population (6/1000).
Although generally considered a T-cell-mediated disease,
potential mechanisms underlying Sjögren's syndrome
range from disturbances in apoptosis [5,6] to circulating
autoantibodies against the ribonucleoproteins Ro and La
[7,8] or cholinergic muscarinic receptors [9–11] in sali-
vary and lacrimal glands in genetically predisposed individ-
uals. Others relate reduced salivary and tear flow to
aberrant glandular aquaporin-5 water channel proteins
[12–14], although this is not unambiguous [15]. Possibly
of greater importance is the recently described selective
Sjögren’s syndrome is a multisystem inflammatory rheumatic disease that is classified into primary and
secondary forms, with cardinal features in the eye (keratoconjunctivitis sicca) and mouth (xerostomia).
The aetiology behind this autoimmune exocrinopathy is probably multifactorial and influenced by
genetic as well as by environmental factors that are as yet unknown. A genetic predisposition to
Sjögren’s syndrome has been suggested on the basis of familial aggregation, animal models and
candidate gene association studies. Recent advances in molecular and genetic methodologies should
further our understanding of this complex disease. The present review synthesizes the current state of
genetics in Sjögren’s syndrome.
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downregulation of aquaporin-1 expression in myoepithelial
cells in salivary glands in primary Sjögren's syndrome [16].
Genetic predisposition to Sjögren’s syndrome
A genetic predisposition to Sjögren’s syndrome appears
to exist, and several families involving two or more cases
of Sjögren’s syndrome have been described [17–23].
However, the level of genetic contribution is not known.
Because large twin studies in Sjögren’s syndrome are
lacking, the twin concordance rate cannot be estimated.
Only a few case reports describing twins with primary
Sjögren’s syndrome are available [24–27]. Twins exhib-
ited a very similar phenotype with almost identical clinical
presentation, including dry eyes and dry mouth; similar
serological data (IgG, IgM, IgA, C3, C4, antinuclear anti-
body, anti-Ro/SSA and anti-La/SSB, rheumatoid factor),
with identical fine specificity in their immune responses to
60 kDa Ro/SSA; and identical labial salivary gland focus
scores [24,27].
Familial clustering of different autoimmune diseases and
co-association of multiple autoimmune diseases in individ-
uals have frequently been reported [28]. Interestingly, it is
common for a Sjögren’s syndrome proband to have rela-
tives with other autoimmune diseases (approximately
30–35%) [17,29,30]. Furthermore, Sjögren’s syndrome
exists in two forms – primary and secondary; the form that
is present depends on whether it occurs alone or together
with other connective diseases, such as systemic lupus
erythematosus or rheumatoid arthritis [31]. Clustering of
non-major histocompatibility complex (MHC) susceptibility
candidate loci in human autoimmune diseases supports a
hypothesis that, in some cases, clinically distinct auto-
immune diseases may be controlled by a common set of
susceptibility genes [32].
Sjögren’s syndrome is considered a complex disorder.
Susceptibility to the disease can be ascribed to an inter-
play between genetic factors and the environment. In
complex diseases, one specific gene is neither necessary
nor sufficient for disease expression. This makes the
genetics behind these diseases more complicated than
those of diseases with a simple Mendelian character.
Sjögren’s syndrome is major histocompatility
complex associated
The polymorphic MHC genes are the best documented
genetic risk factors for the development of autoimmune
diseases overall [33–35]. With regard to Sjögren’s syn-
drome, the most relevant MHC complex genes are the
class II genes, specifically the human leukocyte antigen
(HLA)-DR and HLA-DQ alleles [36]. Patients of different
ethnic origins exhibit different HLA gene associations
[37]. In Caucasians of northern and western European
backgrounds, including North American Caucasians,
Sjögren’s syndrome is among several autoimmune dis-
eases that are associated with the haplotypes B8, DRw52
and DR3. The increased frequency of HLA-B8 was pre-
sumably due to an association with the HLA class II allele
HLA-DRB1*03. However, a novel association of HLA
class I alleles (i.e. HLA-A24) to susceptibility to primary
Sjögren’s syndrome was recently reported [38]. Beyond
that, an association with DR2 has been found in Scandi-
navians [39] and with DR5 in Greeks [40]. All of the hap-
lotypes are in strong linkage disequilibrium, resulting in
certain difficulties in establishing which of the genes con-
tains the locus that confers the risk. DQCAR is a very
polymorphic CA repeat microsatellite located between the
HLA DQA1 and DQB1 gene and specific DQCAR alleles
have been found to be in tight linkage disequilibrium with
known HLA DR-DQ haplotypes. HLA-DQB1 CAR1/CAR2
allele frequencies were found to be significantly different
in patients with Sjögren’s syndrome as compared with
healthy control individuals in a study in which the Kaplan
criteria were used to classify Sjögren’s syndrome [41].
Apparently, the HLA haplotype may influence the severity
of autoimmune disease. It has been claimed that Sjögren’s
syndrome patients with DQ1/DQ2 alleles have a more
severe autoimmune disease than do patients with any
other allelic combination at HLA-DQ [42], and the DR3-
DQ2 haplotype has been indicated as a possible marker
for a more active immune response in Finnish patients with
Sjögren’s disease [43].
HLA is associated with the presence of Ro
and La autoantibodies in Sjögren’s syndrome
Distinct HLA haplotypes have been associated with certain
degrees of autoantibody diversification in Sjögren’s syn-
drome [44]. Autoantibodies to Ro/SSA and La/SSB have
been found to be associated with DR3, DQA and DQB
alleles [45–47]. A dose-dependent contribution of DQα-
34Q and DQβ-26L, in addition to the DRB1*03-
DQB1*02-DQA1*0501 haplotype encompassing the
transethnically associated DQβ-DI motif, represented the
strongest contributors to the formation of an anti-Ro/La
response in Norwegian patients with Sjögren’s syndrome
[45]. A stronger correlation has been found between anti-
Ro/SSA autoantibodies and DR3/DR2 than that with the
disease itself [45,48–50]. In Japanese persons, HLA class
II allele association has been reported to differ among anti-
Ro/SSA-positive individuals according to the presence or
absence of coexisting anti-La/SSB [51].
Cytokine polymorphisms in Sjögren’s syndrome
Cytokines serve to mediate and regulate immune and
inflammatory responses, and have been implicated in the
pathogenesis of a variety of autoimmune diseases, including
Sjögren’s syndrome. Numerous investigators have
attempted to analyze the association of primary Sjögren’s
syndrome with cytokine polymorphisms, but at present no
convincing relationship has been identified (for review [52]).355
Both human and animal studies indicate the involvement
of IL-10 in the pathogenesis of primary Sjögren’s syn-
drome [53] and mice transgenic for IL-10 develop a Fas-
ligand-mediated exocrinopathy that resembles Sjögren’s
syndrome [54]. A recent study described an association
between primary Sjögren’s syndrome and IL-10 promoter
polymorphisms in a cohort of Finnish individuals, and a
specific haplotype was found to correlate with high
plasma levels of IL-10 [55]. Conversely, no association
was found for IL-10 promoter polymorphism and primary
Sjögren’s syndrome or the presence of Ro autoantibodies
in an Australian cohort of primary Sjögren’s syndrome
patients [56].
The IL-1 receptor antagonist regulates IL-1 activity in
inflammatory disorders by binding to IL-1 receptors and
thus inhibiting the activity of IL-1. The human IL-1 receptor
antagonist gene (i.e. IL1RN) has a variable allelic polymor-
phism within intron 2 as a result of variation in number of
an 86-base-pair sequence repeat [52]. An increased fre-
quency and carriage rate of the IL1RN*2 allele has been
found in primary Sjögren’s syndrome [57]. No statistically
significant association can be ascribed to tumour necrosis
factor-α and primary Sjögren’s syndrome [58].
Additional candidate gene studies
Because there is no disease-specific criterion for
Sjögren’s syndrome, the candidate genes studied may be
related to other autoimmune phenotypes also. Mutations
in the apoptosis genes have been identified as a possible
cause or a contributing factor to human diseases [59],
and the role of apoptosis has also been a major topic in
autoimmune diseases, including primary Sjögren’s syn-
drome (for review [5,6]).
An increased frequency of apoptosis in ductal epithelial
cells of the salivary glands leading to reduced salivary flow
has been proposed as a possible disease mechanism
[60,61]. Other investigators have suggested that inflam-
matory mononuclear cells are able to escape apoptosis
because of defects in the death signalling pathway, which
lead to accumulation of lymphocytes to displacement of
functioning acinar cells [6,62]. In the complex cascade of
apoptotic signal molecules, Fas and Fas ligand are central
actors. An insert of a retrotransposon in the Fas gene was
discovered in the murine model MRL/lpr-lpr, which exhibits
progressive focal sialadenitis, and has as such been for-
warded as a possible explanation for aberrant apoptosis in
that experimental model [63–66]. This finding led to spec-
ulation over whether a similar phenomenon may be
present in the human Fas gene. Now, more than 20 dis-
tinct Fas mutations are known in humans, and mutations in
this gene have been identified as cause of or factor con-
tributing to human diseases, such as autoimmune lympho-
proliferative syndrome type I (for review [59]).
Polymorphisms in the Fas and FasL genes have also been
found in primary Sjögren’s syndrome [67]. However, none
of the polymorphisms in Fas or FasL entailed amino acid
changes in patients with primary Sjögren’s syndrome, and
at present there exists no clear-cut mutation or defect in
these genes that is clearly associated with primary
Sjögren’s syndrome and as such can be regarded as a
disease-determining factor. Notably, the apoptosis
cascade is built up of a huge number of signal molecules,
and the possibility that there should be polymorphisms or
mutations of vital importance for development of the
disease among these factors still exists. Thus far, however,
a definite role for apoptosis in primary Sjögren’s syndrome
cannot be confirmed.
The contribution of Ro/SSA and La/SSB in Sjögren’s syn-
drome is not fully understood. It is not known how toler-
ance breakdown and autoantibody response to Ro/SSA
and La/SSB is generated. The ribonucleoproteins are
endogenous proteins that are normally hidden from the
immune system, and should subsequently not give rise to
abnormal B-cell responses. However, stress such as ultra-
violet radiation, viral infections and apoptosis have been
suggested to lead to undesirable cell surface exposure of
autoantigens to the immune system [7]. Ro/SSA and
La/SSB have been demonstrated in surface blebs of
apoptotic ultraviolet-irradiated keratinocytes, implying a
role in systemic lupus erythematosus [68]. Not much is
known from a genetic point of view, but an association
study has been performed in Ro52 [69]. A single nucleotide
polymorphism in intron 3 of the Ro52 gene was found to be
strongly associated with the presence of anti-Ro52 autoan-
tibodies in primary Sjögren’s syndrome [69]. This is interest-
ing because alternative mRNA is made by deleting exon 4,
which encodes a putative leucine zipper domain, to gener-
ate a shorter version of the Ro52 protein [70].
Genes that encode transporters associated with antigen
processing (i.e. TAP genes) have also been associated
with susceptibility to Sjögren’s syndrome [71]. Others
have indicated a putative role for the cysteine-rich secre-
tory protein 3 (CRISP-3) gene as an early response gene
that may participate in the pathophysiology of the auto-
immune lesions of Sjögren’s syndrome [72].
A 44-fold increased risk for the development of B-cell lym-
phoma has been documented in Sjögren’s syndrome, and
a role for activated B cells has been implicated [73].
Notably, it is not known whether B-cell activation is a
primary cause or a secondary manifestation in Sjögren’s
syndrome. Patients are known to have increased levels of
serum IgG [3]. Although the cellular basis of this hyper-
gammaglobulinaemia and the strong associations of
certain autoantibodies with particular MHC class II mole-
cules have been intensively examined, little is known about
the usage of IgV (immunoglobulin variable) region genes,
and especially by autoantibodies in autoimmune diseases.
Available online http://arthritis-research.com/content/4/6/353356
Therefore, a study of IgVλ light chain gene usage in primary
Sjögren’s syndrome patients was undertaken by Kaschner
et al. [74]. Those investigators identified molecular differ-
ences from controls in V-J recombination and concluded
that disturbed regulation of B-cell maturation with abnormal
selection, defects in editing immunoglobulin receptors and
abnormal mutational targeting may contribute to the emer-
gence of autoimmunity in Sjögren’s syndrome.
Rheumatoid factors are autoantibodies against antigenic
determinants that are present on the Fc portion of human
IgG, and are found in sera and saliva of 60–80% of
patients with primary Sjögren’s syndrome [3]. We found
rheumatoid factor to be present in sera of 91% of Norwe-
gian anti-Ro-positive patients with primary Sjögren’s syn-
drome [45]. The genetic origin and the mechanisms
underlying its generation have been investigated in primary
Sjögren’s syndrome [75]. In such patients, rheumatoid
factor used diverse VH region genes, the majority of which
show no evidence of somatic hypermutation, whereas light
chain variable (VL) sequences exhibited a moderate contri-
bution of somatic hypermutation [76].
Understanding primary Sjögren’s syndrome
in view of animal models
An appropriate animal model of Sjögren’s syndrome could
greatly advance our ability to identify the target antigens,
characterize the immune mechanisms and define the
genetic background. Several animal models, both experi-
mentally induced and spontaneous inflammatory reactions
with features of human Sjögren’s syndrome, have been
reported and previously reviewed [77].
The nonobese diabetic (NOD) mouse develops a
disease that mimicks human type 1 diabetes mellitus
and has been intensively studied for this phenotype. It
also spontaneously develops sialadenitis and several
other features of Sjögren’s syndrome, including autoan-
tibodies against Ro/SSA [77]. The NOD mouse carries
the MHC H2g7 haplotype. In order to study the impor-
tance of NOD non-MHC genes, an H2q congenic NOD
mouse, namely NOD.Q, was established [78,79].
Recently, a gene segregation experiment was con-
ducted in a (NOD.Q × B10.Q)F2 cross, and genetic
mapping revealed one locus (Nss1) associated with
sialadenitis on chromosome 4 (LOD score 4.7; Fig. 1)
[78]. The H2g7 haplotype was not critical for sialadenti-
tis development in the NOD background because the
NOD.Q mouse also developed sialadenitis. The genetic
control of sialadenitis appeared to be unique in compar-
ison with diabetes and arthritis, because no loci associ-
ated with these diseases have been identified at the
same location [79]. This supports earlier findings that
the sicca syndrome occurs independently of autoim-
mune diabetes, and NOD MHC I-Ag7 was not essential
for exocrine tissue autoimmunity [80].
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Figure 1
Chromosomal map illustrating the location of identified quantitative trait loci associated with sialadenitis development in various murine models.
Chromosomal positions are based on the map from the Jackson Laboratory (http://informatics.jax.org/). Sialadenitis susceptibility loci are drawn
from *[78], ¶[82], †[83] and ‡[84]; markers with LOD score >3.3 are underscored, however, for the markers Il2, Asm2 and Hsp70 a LOD score
>3.3 was only obtained in females and for the marker D1Mit153 only in males.
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More recently, alleles from chromosomes 1 and 3 of NOD
mice have been found to combine to influence Sjögren’s
syndrome-like autoimmune exocrinopathy [81], and two
intervals contribute synergistically to the development of
Sjögren’s syndrome on a healthy murine background; this
has also been demonstrated in the NOD mouse after
crossing (Fig. 1) [82]. Very recently, chromosome 1 was
reported to be a major susceptibility region for develop-
ment of autoimmune sialadenitis [83]. In different matings
of NOD mice, including a (NOD × C57BL/6 [B6])F2 cross,
a (NOD × NZW)F2 cross, and a ([NOD × B6] × NOD)
backcross, an association with the middle region of chro-
mosome 1 was detected in all crosses.
The NZB, MRL/lpr, NOD and NFS/sld strains are all
experimental murine models that spontaneously develop
salivary gland inflammation, of which the MRL/lpr and the
NOD strains present with serum anti-Ro/SSA antibodies.
An insertion of an ET-transposon in the Fas gene has
been found to be responsible for the lpr genotype in the
MRL/lpr mouse [65]. Similar Fas gene insertions could not
be traced in Sjögren’s syndrome patients [67]. A genome-
wide scan of MRL/lpr mice revealed four susceptible loci,
mapped on chrosome 10, 18, 4 and 1, which were reces-
sively associated with sialadenitis [84]. The sialadenitis in
MRL/lpr mice is probably under the control of polygenic
inheritance, because the loci manifested an additive effect
in a hierarchical manner. The different susceptibility loci
reported for sialadenitis are outlined in Fig. 1.
Transgenic mice have frequently been used as models to
study the role of viruses in the pathogenesis of a variety of
diseases and to determine the importance of cytokines
such as IL-10 [54]. Transgenic expression of IL-10
induced apoptosis of glandular tissue and promoted infil-
tration of lymphocytes. Transgenic mice containing the
human T-cell lymphotropic virus type-1 tax gene under the
control of the viral long terminal repeat (LTR) develop an
exocrinopathy that involves the salivary and lacrimal
glands, resembling the pathology of Sjögren’s syndrome
[85]. It was suggested that human T-cell lymphotropic
virus type-1 may represent a primary event in the develop-
ment of exocrinopathy by virally induced proliferation and
perturbation of the function of ductal epithelium. Sialadeni-
tis and inflammation in lachrymal glands histologically
resembling Sjögren’s syndrome have also been found in
mice transgenic for hepatitis C virus envelope genes [86].
Conclusion
Very little is known about the genetics of Sjögren’s syn-
drome. Although not conclusive, however, recent findings
in animal breeding studies are promising with respect to
resolving issues in Sjögren’s syndrome. Of special interest
were the major susceptibility loci for autoimmune
sialadenitis demonstrated on chromosomes 1, 4 and 10 in
murine models. For instance, the chromosomal regions
around Nss1 on chromosome 4 harbour a set of genes
that are probably of importance for different kinds of
autoimmune syndromes, because several loci associated
with autoimmune disease models for systemic lupus ery-
thematosus and autoimmune haemolytic anaemia are clus-
tered around Nss1 (for review [78]). Interestingly, no
association between sialadenitis in the NOD.Q and colla-
gen-induced arthritis was observed [78].
Human linkage studies of Sjögren’s syndrome families, in
addition to analyses of gene expression signatures on
microarrays, will probably be an important source of infor-
mation in the future. Identification of new genetic markers
may lead to development of better diagnostic and prog-
nostic tests in Sjögren’s syndrome, including its systemic
complications. However, as with the other rheumatic dis-
eases, it is anticipated that both overlap and discrepan-
cies will be detected during genome screens. Given the
likely heterogeneity of Sjögren’s syndrome, advances will
probably not be made without future global collaboration.
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